Study of patients treated with Tecentriq (atezolizumab) shows the risk of hyperprogression is .7% when the PD-L1 is used as a first-line therapy and 8.8% when it was used in later lines of therapy.
Hyperprogression—paradoxically accelerated tumor growth—has been reported in a subset of patients with non-small cell lung cancer being (NSCLC) treated with second- or later-line monotherapy immune checkpoint inhibitors (ICIs) such as Keytruda (pembrolizumab), Opdivo (nivolumab) and Tecentriq (atezolizumab). But the risk is “markedly lower” with first-line ICIs, particularly chemoimmunotherapy, according to a study pubished in The Oncologist by Lee Li of Flinders University in Australia, and an international team of investigators.
Their study, to their knowledge, is the largest to evaluate risk factors of ICI hyperprogression and one of the most thorough evaluations of contemporary biomarkers. Earlier studies that investigated hyperprogression in single-agent, second/later-line ICI settings provided “limited insights” into the phenomenon’s occurrence with first-line and/or chemoimmunotherapy treatment, the researchers say. Moreover, prior studies examining clinicopathological features had small sample sizes and did minimal investigation of key biomarkers, such as tumor mutation burden or immunophenotypes, said Li and colleagues.
In contrast, these researchers reviewed data on 4,644 patients from seven clinical trials who were treated with Tecentriq as a first-, second-, and later-line therapy of locally advanced or metastatic NSCLC, either as monotherapy or chemoimmunotherapy. Secondarily, they wanted to identify biomarkers that could predict hyperprogression. Tecentriq is a PD-L1 inhibitor, a group that also includes Bavencio (avelumab) and Imfinzi (durvalumab).
The study involved 3,129 patients who received therapy containing Tecentriq and 1,515 who did not. Of the patients who received Tecentriq as first-line therapy, 92% were treated with chemoimmunotherapy and 8% with Tecentriq monotherapy. Median follow-up was 17.3 months.
Among those who were treated with Tecentriq, 119 experienced hyperprogression; 106 were receiving second- or later-line treatment. The risk was 0.7% for first-line treatment compared with 8.8% for later-line monotherapies. There was no statistically significant difference in risk between first-line atezolizumab-chemotherapy and chemotherapy alone.
Younger age, liver metastases, and higher metastatic site count increased the risk of hyperprogression. Median survival with hyperprogression was similar in both groups: 4.3 months in the first-line patients, 6.1 months in the second- or later-line patients.
Biomarkers associated with a higher risk of hyperprogression included higher neutrophil-to-lymphocyte ratio (the single strongest predictor), platelet count, and C-reactive protein levels. Notably, Li and colleagues said, tumor mutation burden and PD-L1 expression were not meaningfully associated with risk of hyperprogression.
Study Suggests Role of Immunogenetic Associations in Lung Cancer Risk
March 7th 2024In the U.S., nearly 200,000 new cases of lung cancer were reported in 2020, with over 100,000 deaths. While the number of lung cancer deaths has generally decreased over the past 20 years, lung cancer remains the leading cause of cancer deaths in the US and is the third most common type of cancer.
Read More
Study: Long-Term Smoking Cessation Linked to Lower Cancer Risk, Even with Relapses
February 6th 2024It is well-known that smoking is linked to a higher risk of cancer, and those who smoke can lower their risk by quitting. However, it remains unclear exactly how many years of continued smoking cessation are needed to see a substantial risk reduction.
Read More